Slide 1: Luveltamab Tazevibulin (STRO-002) Demonstrates Clinical Activity in Recurrent Endometrial Cancer
Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Demonstrates Clinical Activity in Recurrent Epithelial Endometrial Cancer: STRO-002-GM1 Phase 1 Dose Expansion Bhavana Pothuri,1 R. Wendel Naumann,2 Lainie P. Martin,3 David M. O'Malley,4 Denise Uyar,5 John W.
Slide 2: Declaration of Interests
Declaration of Interests Bhavana Pothuri, MD • Research support: AstraZeneca, Clovis Oncology, Tesaro/GSK, ImmunoGen, Onconova, Roche/Genentech, SeaGen, Merck, Mersana, Celsion/Imunon, Karyopharm, Sutro, Imab, Toray • Advisory board: Clovis Oncology, Tesaro/GSK Inc, Lilly/AstraZeneca, Merck, Eisai,
Slide 3: Luvelta, an ADC Directed Against Folate Receptor Alpha, Has Potential as Targeted Therapy
Luveltamab Tazevibulin (Luvelta), an ADC Directed Against Folate Receptor Alpha (FolRα), Has Potential as Targeted Therapy for Recurrent FolRα-Expressing EC • Endometrial cancer (EC) is the only gynecologic malignancy with Luveltamab Tazevibulin increasing incidence and mortality1 (Luvelta) or STRO-
Slide 4: STRO-002-GM1: Phase 1 Dose-Expansion Cohort of Luvelta in Recurrent EC
STRO-002-GM1: Phase 1 Dose-Expansion Cohort of Luvelta in Recurrent EC 17 Patients Enrolled Key Inclusion and Exclusion Criteria • Epithelial endometrial cancer ‒ Excluded: leiomyosarcoma, stromal Luvelta Dosing Schedule Endpoints sarcomas and carcinosarcomas • ≥1% FolRα expression by • Q3W cycles •
Slide 5: Patient Characteristics, Disposition, and Study Drug Exposure
Patient Characteristics, Disposition, and Study Drug Exposure Total Baseline Characteristics N=17 Total Patients Screened Median age (range), years 68 (60–79) N=44 Race, n (%) Asian 0 FolRα ≥1% Black or African America 1 (6) White 15 (88) N=30 (68%) Unknown 1 (6) Ethnicity, n (%) Hispanic or Latino
Slide 6: Luvelta Showed Early Evidence Of Anti-tumor Activity in FolRα Expressing EC
Luvelta Showed Early Evidence Of Anti-tumor Activity in FolRα Expressing EC Maximum Reduction in Target Lesions* Treatment Duration and Dose Modifications TPS, % TPS (%) 5 15 1 2 99 6 25 45 15 35 8 45 75 18 70 30 6 Individual patients treated with luveltamab 30 18 45 20% 45 PR PR PR 8 Dose Level, Q3
Slide 7: TEAEs Consisted of Hematologic Events, Gastric Events and Arthralgia
TEAEs Consisted of Hematologic Events, Gastric Events and Arthralgia No New Safety Signals Observed in EC Compared to Prior Data in EOC TEAEs any grade (>25%) 4.3 mg/kg 5.2 mg/kg Total (n=9) (n=8) (n=17) TEAEs, n (%) Any grade* Grade ≥3 Any grade Grade ≥3 Any grade* Grade ≥3 Patients reporting at le
Slide 8: Conclusions
Conclusions • Recurrent EC had a high incidence of FolRα expression ≥1% – 68% among 44 patients screened in this trial • Luvelta (STRO-002) demonstrated encouraging preliminary anti-tumor activity in patients with FolRα- expressing EC with minimum and higher expression levels – PR in 29% with DCR† o
Slide 9: Acknowledgements
Acknowledgements • We thank the patients who participated in the study, their families, and the investigators and clinical research staff from the study centers • This study was sponsored by Sutro Biopharma, Inc. • Editorial support was provided by Izabela Bombik, PhD of Parexel and funded by Sutro